ea0092ps1-03-04 | Miscellaneous 1 | ETA2023
Garcia Marta
, Carlos Galofre Juan
, Vazquez Beatriz
, Fernandez de Sanmamed Miguel
, Olmedo Maria
, Chumbiauca Estefania
, Martin-Calvo Nerea
Introduction: Immune checkpoint inhibitors (ICIs) are an effective treatment for advanced cancer, but they are not free from immune-related adverse events (irAEs). A common irAES is thyroid dysfunction (TD-irAEs) and, as such, may influence patient survival and response to ICIs.Objetives: The aim was to determine the incidence and characteristics of TD-irAEs among patients with advanced cancer treated with ICIs in a real-life setting and to investigate t...